Bio-Rad Laboratories (NYSE:BIO.B) Posts Earnings Results

Bio-Rad Laboratories (NYSE:BIO.B) announced its quarterly earnings data on Wednesday. The company reported $2.65 EPS for the quarter, Zacks reports. Bio-Rad Laboratories had a return on equity of 3.54% and a net margin of 8.59%.

Bio-Rad Laboratories Stock Performance

NYSE BIO.B remained flat at $379.50 during trading hours on Wednesday. The company had a trading volume of 12 shares, compared to its average volume of 38. The stock has a 50-day simple moving average of $366.64 and a 200 day simple moving average of $311.96. The company has a quick ratio of 2.33, a current ratio of 3.14 and a debt-to-equity ratio of 0.11. Bio-Rad Laboratories has a 1 year low of $244.54 and a 1 year high of $379.50. The firm has a market capitalization of $10.15 billion, a price-to-earnings ratio of 46.00 and a beta of 1.00.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc (NYSE: BIO.B) develops, manufactures and markets products and systems used in life science research and clinical diagnostics. The company serves academic, pharmaceutical, biotechnology, industrial and healthcare customers with laboratory instruments, reagents, consumables, software and related services.

Its life science portfolio includes technologies for genomics, digital PCR, protein analysis, chromatography, electrophoresis, cell biology and imaging. Bio-Rad’s clinical diagnostics business provides systems and reagents used in areas such as diabetes monitoring, blood typing, quality control, infectious disease testing and autoimmune diagnostics.

Founded in 1952 by David and Alice Schwartz, Bio-Rad is headquartered in Hercules, California, and serves customers through operations and distribution networks in North America, Europe, Asia-Pacific and other international markets.